Trial Profile
A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Plinabulin (Primary) ; Docetaxel; Pegfilgrastim
- Indications Neutropenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Protective-1
- Sponsors BeyondSpring Pharmaceuticals
- 06 Jun 2023 Pooled analysis of NCT02504489; NCT03102606; NCT00630110 trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 13 Dec 2022 According to BeyondSpring Pharmaceuticals media release, data of this study was presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) and at ESMO Asia Congress 2022.
- 13 Sep 2022 Results by obtaining data from PROTECTIVE-1 and PROTECTIVE-2, evaluating plins protective effects on granulocyte-monocyte progenitor , presented at the 47th European Society for Medical Oncology Congress